These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacology and pharmacokinetics of fosphenytoin. Browne TR; Kugler AR; Eldon MA Neurology; 1996 Jun; 46(6 Suppl 1):S3-7. PubMed ID: 8649612 [TBL] [Abstract][Full Text] [Related]
4. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Fischer JH; Patel TV; Fischer PA Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978 [TBL] [Abstract][Full Text] [Related]
5. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370 [TBL] [Abstract][Full Text] [Related]
6. Safety of fosphenytoin sodium. Fierro LS; Savulich DH; Benezra DA Am J Health Syst Pharm; 1996 Nov; 53(22):2707-12. PubMed ID: 8931812 [TBL] [Abstract][Full Text] [Related]
7. Fosphenytoin: a novel phenytoin prodrug. Boucher BA Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074 [TBL] [Abstract][Full Text] [Related]
9. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. Knapp LE; Kugler AR J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747 [TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of fosphenytoin for the treatment of status epilepticus. Popławska M; Borowicz KK; Czuczwar SJ Expert Rev Neurother; 2015; 15(9):983-92. PubMed ID: 26289487 [TBL] [Abstract][Full Text] [Related]
12. Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin. Keegan MT; Bondy LR; Blackshear JL; Lanier WL Mayo Clin Proc; 2002 Jun; 77(6):584-6. PubMed ID: 12059129 [TBL] [Abstract][Full Text] [Related]
13. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Ramsay RE; Wilder BJ; Uthman BM; Garnett WR; Pellock JM; Barkley GL; Leppik IE; Knapp LE Epilepsy Res; 1997 Oct; 28(3):181-7. PubMed ID: 9332883 [TBL] [Abstract][Full Text] [Related]
14. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Wilder BJ; Campbell K; Ramsay RE; Garnett WR; Pellock JM; Henkin SA; Kugler AR Arch Neurol; 1996 Aug; 53(8):764-8. PubMed ID: 8759983 [TBL] [Abstract][Full Text] [Related]
15. Fosphenytoin use in children. Pellock JM Neurology; 1996 Jun; 46(6 Suppl 1):S14-6. PubMed ID: 8649608 [TBL] [Abstract][Full Text] [Related]
16. Intramuscular use of fosphenytoin: an overview. Uthman BM; Wilder BJ; Ramsay RE Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611 [TBL] [Abstract][Full Text] [Related]
17. Fosphenytoin sodium: new drug to replace intravenous phenytoin sodium. Voytko SM; Farrington E Pediatr Nurs; 1997; 23(5):503-6. PubMed ID: 9355589 [No Abstract] [Full Text] [Related]
18. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. Löscher W; Reissmüller E; Ebert U Epilepsy Res; 1998 Mar; 30(1):69-76. PubMed ID: 9551846 [TBL] [Abstract][Full Text] [Related]
19. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. DeToledo JC; Ramsay RE Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039 [TBL] [Abstract][Full Text] [Related]
20. Probabilistic approach to the establishment of maximal content limits of impurities in drug formulations: the case of parenteral diphenylhydantoic acid. Manca D; Walker RM; Krishna G; Graziano MJ; Kropko ML Regul Toxicol Pharmacol; 1999 Feb; 29(1):1-14. PubMed ID: 10051414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]